Immune responses to infections and vaccines may be different in children, compared to adults. A careful evaluation of novel vaccines in the pediatric population is therefore warranted.
The clinical efficacy of several vaccines in protecting against symptomatic COVID-19, especially in light of the circulating variants, has been an emerging research topic.
As vaccines roll out, studies are underway to continue to monitor their efficacy against SARS-CoV-2 infection, and particularly, against asymptomatic infections.
A large, national, multicentre prospective cohort study of hospital healthcare workers in the UK (The SARS-CoV-2 Immunity and Reinfection Evaluation, SIREN) reports, in an interim analysis published in The Lancet, that participants who previously had SARS-CoV-2 antibodies had an 84% lower risk of (re)infection.
Interim analysis suggests the Oxford-AstraZeneca vaccine is not effective against the South African variant
A randomized control trial in South Africa, the results of which have been published in the New England Journal of Medicine, has found that the Oxford-AstraZeneca vaccine, although safe, is not effective against the B.1.351 variant, also known as the South African variant.
Modelling uncertain times: what are the epidemiological and viral variant outcomes of alternative vaccination schemes?
Due to vaccine shortages, researchers are considering alternative options to the standard recommended vaccination schedules allowing more people to be vaccinated at an earlier date.
In recent months, studies have raised the possibility that certain emerging SARS-CoV-2 variants evolved to escape antibody immune surveillance, elicited by previous infection, immunization, or by monoclonal antibody treatments.
Viruses mutate naturally as they replicate. Generally, most mutations are not a serious concern for human health or public health strategies.
This study reported that individuals with pre-existing immunity have 10-20 times higher SARS-CoV-2 antibody titers than naïve individuals after the first dose.
OP-ED, CHARU KAUSHIC AND CATHERINE HANKINS, CONTRIBUTED TO THE GLOBE AND MAIL, JANUARY 7, 2021 Charu Kaushic is a professor of pathology and molecular medicine at McMaster University. Catherine Hankins is a professor of public and population Health at McGill University. Both are members of the COVID-19 Immunity Task Force. This year is starting on [...]